ArthroCare
This article was originally published in The Gray Sheet
Executive Summary
Proposed secondary offering of 1 mil. common stock shares is outlined in a registration statement filed with the Securities and Exchange Commission. Net proceeds will be used for further development and commercialization of products based on the firm's Coblation low-temperature tissue ablation technology, and for corporate and other general purposes. The Sunnyvale, California firm plans to pursue additional spinal applications within the next year (1"The Gray Sheet" Sept. 13, p. 12). Underwriters BancBoston Robertson Stephens and Bear Stearns have an overallotment option for an additional 150,000 shares